SUCCESSOR-2 is an EHA 2026 late-breaking Phase 3 multiple myeloma study, listed as LB5004, evaluating…
Browsing: Life Science
Want to get ideas and solutions for your R&D in Life Science? Check out the resources powered by Patsnap Eureka, find the technical resources you need.
Agios Pharmaceuticals is included for EHA 2026 market mapping because its portfolio or pipeline focus…
Astellas Pharma is included for EHA 2026 market mapping because its portfolio or pipeline focus…
Menin Inhibitor is included as an EHA 2026 modality keyword because it captures a recurring…
CELMoD is included as an EHA 2026 modality keyword because it captures a recurring technology…
Primary CNS Lymphoma is included as an EHA 2026 disease-area keyword under hematologic malignancy, with…
Sickle Cell Disease is included as an EHA 2026 disease-area keyword under non-malignant hematology, with…
CD123 is a key EHA 2026 target keyword associated with switchable allogeneic car-t. It should…
GPRC5D is a key EHA 2026 target keyword associated with car-t, bispecific antibody. It should…
BCMA is a key EHA 2026 target keyword associated with car-t, bispecific antibody, antibody-drug conjugate.…